|
|
|
|
Vol. 63, Issue 1, 105-110, January 2003
Department of Pharmacology, Yale University School of Medicine, New
Haven, Connecticut
Deoxycytidylate deaminase, catalyzing the conversion of dCMP to dUMP,
is an important enzyme in the de novo synthesis of thymidine nucleotides. It also may be involved in the action, as well as the metabolism of anticancer agents. Recently, several L-
and D-configuration pyrimidine deoxynucleoside analogs were
found to be potent antiviral and antitumor agents. Their interaction with dCMP deaminase as a monophosphate or a triphosphate metabolite is
not clear. These include D-nucleoside analogs such as
-D-2',3'-dideoxycytidine (ddC),
-2'-fluoro-5-methyl-arabinofuranosyluracil (FMAU),
3'-azido-2',3'-dideoxythymidine (AZT), and
2',3'-didehydro-2',3'-dideoxythymidine (D4T) as well as
L-nucleoside analogs such as
-L-dioxolane-cytidine (L-OddC),
-L-2',3'-dideoxy-3'-thiacytidine,
-L-2',3'-dideoxy-5'-fluoro-3'-thia-cytidine (L-FSddC),
-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine, and
L-FMAU. None of the L-deoxycytidine analog
monophosphates act as substrates or inhibitors. Among these pyrimidine
deoxynucleoside analog monophosphates, D-FMAU monophosphate
(MP) is the most potent competitive inhibitor, whereas
L-FMAUMP has no inhibitory activity. Interestingly, AZTMP
and D4TMP also have potent inhibitory activities on dCMP deaminase.
Among the dCTP and TTP analogs examined, D- and
L-FMAUTP were the most potent inhibitors and had the same extent of inhibitory effect. These results suggest that a chiral specificity for the substrate-binding site may exist, but there is no
chiral specificity for the regulator-binding site. This is also
supported by the observation that L-OddC and
L-FSddC have inhibitory activities as triphosphates but not
as monophosphates. None of the D- and L-dCTP
analogs activated dCMP deaminase as dCTP. The biological activities of
AZT and D4T could be partially attributable to their inhibitory
activity against dCMP deaminase by their phosphorylated metabolites,
whereas that of ddC and the L-deoxycytidine analogs may not
involve dCMP deaminase directly.
This article has been cited by other articles:
![]() |
E. Murakami, C. Niu, H. Bao, H. M. Micolochick Steuer, T. Whitaker, T. Nachman, M. A. Sofia, P. Wang, M. J. Otto, and P. A. Furman The Mechanism of Action of {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase Antimicrob. Agents Chemother., February 1, 2008; 52(2): 458 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A.C. Alexandre, B. Roy, D. Topalis, S. Pochet, C. Perigaud, and D. Deville-Bonne Enantioselectivity of human AMP, dTMP and UMP-CMP kinases Nucleic Acids Res., July 10, 2007; (2007) gkm479v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Liaw, Y.-J. Chang, C.-T. Lai, H.-C. Chang, and G.-G. Chang Crystal Structure of Bacillus subtilis Guanine Deaminase: THE FIRST DOMAIN-SWAPPED STRUCTURE IN THE CYTIDINE DEAMINASE SUPERFAMILY J. Biol. Chem., August 20, 2004; 279(34): 35479 - 35485. [Abstract] [Full Text] [PDF] |
||||